Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. EU regulators set Oct. 3 deadline to decide on Eli Lilly , Novartis deal

      Headlines

      Mon, 1 Sep 2014

      EU antitrust authorities will decide whether to clear Eli Lilly 's (NYSE: LLY ) $5.4B offer for Novartis (NYSE: NVS ) by Oct. 3. The acquisition is part of several deals recently announced

    2. EU regulators set Oct. 3 deadline for Eli Lilly , Novartis deal

      Headlines

      Mon, 1 Sep 2014

      BRUSSELS, Sept 1 (Reuters) - European Union competition regulators have until Oct. 3 to decide whether to approve U.S. drugmaker Eli Lilly and Co's $5.4 billion bid for Swiss peer Novartis's animal...

    3. Takeda loses bid to overturn $9B damage award

      Headlines

      Fri, 29 Aug 2014

      made a separate of the verdict in April. Legal observers do not believe that the full amount of the award will stand. Eli Lilly (NYSE: LLY ) co-promoted Actos from 1999 to 2006. It says that Takeda agreed to indemnify it for its losses and expenses

    4. Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

      Headlines

      Thu, 28 Aug 2014

      Aug 28 (Reuters) - Takeda Pharmaceuticals and Eli Lilly & Co lost a bid to overthrow a combined $9 billion punitive-damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.

    5. New Morningstar Analyst Report for Novartis AG

      Stock Reports

      Thu, 21 Aug 2014

      announced in April with Glaxo and Eli Lilly , Novartis appears to have come out ..... divestiture of both the animal health (to Eli Lilly ) and vaccine unit (to Glaxo) that ..... announced in April with Glaxo and Eli Lilly , Novartis appears to have come out

    6. Lilly psoriasis mAb successful in Phase 3 trial

      Headlines

      Thu, 21 Aug 2014

      Eli Lilly ( LLY +0.5% ) Bio-Medicines chief David Ricks says that "complete resolution of psoriasis is possible for significantly

    7. New Morningstar Analyst Report for Eli Lilly and Co

      Stock Reports

      Thu, 21 Aug 2014

      even though Lechleiter is an insider, we believe he will instill the needed changes to address the patent challenges. Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products

    8. FDA Uncertainty May Delay Next Milestone; Global Rollout of Axiron on Track; Fair Value Unchanged

      Commentary

      Thu, 21 Aug 2014

      support global marketing of Axiron by Eli Lilly . During fiscal 2014, Axiron was ..... under the licensing agreement from Eli Lilly . We have factored this milestone ..... million milestone payment paid by Eli Lilly . A final dividend of AUD 0.08

    9. Lilly gets tentative approval for diabetes drug

      Headlines

      Tue, 19 Aug 2014

      The FDA grants tentative approval for Eli Lilly ( LLY +0.5% ) and Boehringer Ingelheim's Basaglar (insulin glargine injection) as a treatment to improve glycemic control

    10. UPDATE 1- Eli Lilly insulin drug receives tentative U.S. approval

      Headlines

      Mon, 18 Aug 2014

      Aug 18 (Reuters) - The U.S. Food and Drug Administration granted tentative approval for Eli Lilly and Co and Boehringer Ingelheim's insulin injection that helps control blood sugar levels in diabetes patients, Lilly said in a statement.

    « Prev12345Next »
    Content Partners